The neural crest transcription factor SOX 10 is preferentially expressed in triple negative breast carcinomas: The expresion of Sox 10 in triple negative infiltating ductal carcinomas supports the concept that these neoplasms show myoepithelial differentation

Antonio Arra; Daniel Coso; Rosana Ramos Dos Santos

doi:10.59471/ijhsc20211

Authors

Antonio Arra Universidad Abierta Interamericana. Facultad de Medicina y Ciencias de la Salud. Buenos Aires, Argentina Author https://orcid.org/0000-0002-8163-3189
Daniel Coso Universidad Abierta Interamericana. Facultad de Medicina y Ciencias de la Salud. Buenos Aires, Argentina Author
Ramos Dos Santos Rosana Universidad Abierta Interamericana. Facultad de Medicina y Ciencias de la Salud. Buenos Aires, Argentina Author

DOI:

https://doi.org/10.59471/ijhsc20211

Keywords:

Breast Carcinoma, Triple Negative, SOX10, Ductal Carcinomas, Myoepithelial Cells

Abstract

Introduction: The expression of SOX 10 by immunohistochemistry has been documented in benign breast myoepithelial cells and in ductal carcinomas classified by the molecular subtype defined by immunohistochemistry. Material and methods: Material and methods: 77 cases of infiltrating ductal carcinomas of the mammary gland with Sox 10 reactivity were analyzed and subdivided by immunohistochemistry into the different molecular subtypes. The IHC panel used to define molecular subtypes included Estrogen Receptors (ER), Progesterone Receptors (PR), Her 2, cytokeratin(CK) 5/6, Epidermal Growth Factor Receptor (EGFR). Results: In our study we demonstrated in 31 cases (44.25%) of 77 infiltrating ductal carcinomas SOX 10 immunoreactivity, which was only observed in basal and undifferentiated subtype triple negative carcinomas. Conclusion: The expression of Sox 10 in triple negative infiltrating ductal carcinomas supports the concept that these neoplasms show myoepithelial differentiation

References

Mollaaghababa R, Pavan WJ. The importance of having your SOX on: Role of SOX10 in the development of neural crest-derived melan ocytes and glia. Oncogene. 2003; 22: 3024- 30 34 [PubMed] [Google scholar] .

11. 12.13. 14. 15.16.cleic Acids Res. 1993; 21: 744 [PMC free article] [PubMed] [Google scholar].

Pusch C, Hustert E, Pfeifer D, et al. The SOX10 / Sox10 gene from human and mouse: Sequence, expression, and transactivation by the encoded HMG domain transcription factor. Hum Genet. 1998; 103: 115- 1 23 [PubMed] [Google scholar].

Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Scien- ce. 1999; 284: 770-776 [PubMed] [Google scholar].

Bouras T, Pal B, Vaillant F, et al. Notch Signaling Regula- tes Mammary Stem Cell Function and Luminal Cell-Fate Commi tment. Cell Stem Cell. 2008; 3: 429- 4 41 [PubMed] [Google scholar].

Reis-Filho JS, Tutt ANJ. Triple negative tumours: A critical re view. Histopathology. 2008; 52: 108-118 [PubMed] [Goo- gle scholar].

Foulkes WD, Smith IE, Reis – Filho JS. Triple-negative breat cancer. N Engl J Med. 2010; 363: 1938-1948 [PubMed] [Google scholar].

Badve S, Dabbs DJ, Schnitt SJ, et al. Basal-like and triple-ne- gative breast cancers: A critical review with an emphasis on the implications for pathologists and onc ologists. Mod Pa- thol. 2011; 24: 157– 167 [PubMed] [Google scholar]. Reis-Filho JS, Milanezi F, Paredes J, et al. Novel and classic myoepithelial / stem cell markers in metaplastic carcinomas of the breast. Appl Immunoh istochem Mol Morphol. 2003; 11 : 1–8. [PubMed]

3.

Kelsh RN. Sorting out Sox10 functions in neural crest deve- lopment. BioEssays. 2006; 28: 788–798 [PubMed] [Google scholar] .

Nonaka D, Chiriboga L, Rubin BP. Sox10: A Pan-Schwan- nian and melanocytic mark er. Am J Surg Pathol. 2008; 32: 1291–1298 [PubMed] [Google scholar].

Karamchandani JR, Nielsen TO, Van De Rijn M, West RB. Sox10 and s100 in the diagnosis of soft-tissue neoplas- ms. Appl Immunohistochem Mol Morphol. 2012; 20: 445– 450 [PubMed] [Google scholar].

Shin J, Vincent JG, Cuda JD, Xu H, Kang S, Kim J, et al. Sox10 is expressed in primary melanocytic neoplasms of various histologies but not in fibrohistiocytic proliferations and his- tiocytoses. J Am Acad Dermatol 2012; 67: 717- 7 26. [Pub- Med] [Google scholar].

Ashley Cimino-Mathews, Andrea P Subhawong, Hillary Elwood et al. Neural crest transcription factor Sox 10 is preferentially expressed in triple-negative and metaplastic breast carcinomas. Hum Pathol. 2013; 44 (6) : 959-965.

Felipe Imigo, Edgardo Mansilla, Ignacio Delama et al. Mo- lecular classification of breast cancer. Quad. cir. 2011; 25: 67-74.

Wegner M. From head to toes: the multiple facets of Sox pro- tei ns. Nucleic Acids Res. 1999; 2 7: 1409–1420 [PMC free article] [PubMed] [Google scholar].

Wright EM, Snopek B, Koopman P. Seven new members of the Sox gene family expressed during mouse developme nt. Nu-

Dravis C, et al. Sox10 Regulates Stem / Progenitor and Me- senchymal Cell States in Mammary Epithelial Cells. Cell Rep 2015 Sep 9. Pii: S 2211-1237 (15) 00925-0. Doi: 10: 1016 / j. celre 2015.08.040.